APO Research
Talk to an analyst

APO RESEARCH · REPORT

FGF-2 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global FGF-2 Inhibitors Market Analysis and Forecast 2026-2032

30 December 2025209 pages

Choose your research edition.

Industry ResearchFGF-2 Inhibitors Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal FGF-2 Inhibitors Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal FGF-2 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FGF-2 Inhibitors Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal FGF-2 Inhibitors Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global FGF-2 Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for FGF-2 Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for FGF-2 Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for FGF-2 Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for FGF-2 Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of FGF-2 Inhibitors include Advenchen Laboratories, ArQule, AVEO Pharmaceuticals, Batu Biologics, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celon Pharma, Debiopharm International and Eddingpharm, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for FGF-2 Inhibitors, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of FGF-2 Inhibitors, also provides the revenue of main regions and countries. Of the upcoming market potential for FGF-2 Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the FGF-2 Inhibitors revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global FGF-2 Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for FGF-2 Inhibitors revenue, projected growth trends, production technology, application and end-user industry.

FGF-2 Inhibitors Segment by Company

Advenchen Laboratories

ArQule

AVEO Pharmaceuticals

Batu Biologics

Boehringer Ingelheim

Bristol-Myers Squibb Company

Celon Pharma

Debiopharm International

Eddingpharm

Eli Lilly and Company

Hutchison MediPharma

Principia Biopharma

Santa Cruz Biotechnology

Vichem Chemie Research

AstraZeneca

Amgen

Novartis

Eisai

FGF-2 Inhibitors Segment by Type

EDP-317

Debio-1347

CPL-043

BAY-1163877

AZD-4547

ASP-5878

Others

FGF-2 Inhibitors Segment by Application

Clinic

Hospital

Others

FGF-2 Inhibitors Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FGF-2 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FGF-2 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FGF-2 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of FGF-2 Inhibitors in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of FGF-2 Inhibitors company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, FGF-2 Inhibitors revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global FGF-2 Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. EDP-317 Major Player Table 3. Debio-1347 Major Player Table 4. CPL-043 Major Player Table 5. BAY-1163877 Major Player Table 6. AZD-4547 Major Player Table 7. ASP-5878 Major Player Table 8. Others Major Player Table 9. Global FGF-2 Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Clinic Major Player Table 11. Hospital Major Player Table 12. Others Major Player Table 13. FGF-2 Inhibitors Industry Trends Table 14. FGF-2 Inhibitors Industry Drivers Table 15. FGF-2 Inhibitors Industry Opportunities and Challenges Table 16. FGF-2 Inhibitors Industry Restraints Table 17. Global FGF-2 Inhibitors Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global FGF-2 Inhibitors Market Size by Region (2021-2026) & (US$ Million) Table 19. Global FGF-2 Inhibitors Market Share by Region (2021-2026) Table 20. Global FGF-2 Inhibitors Market Size by Region (2027-2032) & (US$ Million) Table 21. Global FGF-2 Inhibitors Market Share by Region (2027-2032) Table 22. Global FGF-2 Inhibitors Revenue by Players (US$ Million) & (2021-2026) Table 23. Global FGF-2 Inhibitors Revenue Market Share by Players (2021-2026) Table 24. Global FGF-2 Inhibitors Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global FGF-2 Inhibitors Key Players Headquarters & Area Served Table 26. Global FGF-2 Inhibitors Players, Product Type & Application Table 27. Global FGF-2 Inhibitors Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global FGF-2 Inhibitors by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global FGF-2 Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global FGF-2 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 32. Global FGF-2 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 33. Global FGF-2 Inhibitors Revenue Market Share by Type (2021-2026) Table 34. Global FGF-2 Inhibitors Revenue Market Share by Type (2027-2032) Table 35. Global FGF-2 Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global FGF-2 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 37. Global FGF-2 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 38. Global FGF-2 Inhibitors Revenue Market Share by Application (2021-2026) Table 39. Global FGF-2 Inhibitors Revenue Market Share by Application (2027-2032) Table 40. Advenchen Laboratories Company Information Table 41. Advenchen Laboratories Business Overview Table 42. Advenchen Laboratories FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Advenchen Laboratories FGF-2 Inhibitors Product Portfolio Table 44. Advenchen Laboratories Recent Development Table 45. ArQule Company Information Table 46. ArQule Business Overview Table 47. ArQule FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. ArQule FGF-2 Inhibitors Product Portfolio Table 49. ArQule Recent Development Table 50. AVEO Pharmaceuticals Company Information Table 51. AVEO Pharmaceuticals Business Overview Table 52. AVEO Pharmaceuticals FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. AVEO Pharmaceuticals FGF-2 Inhibitors Product Portfolio Table 54. AVEO Pharmaceuticals Recent Development Table 55. Batu Biologics Company Information Table 56. Batu Biologics Business Overview Table 57. Batu Biologics FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Batu Biologics FGF-2 Inhibitors Product Portfolio Table 59. Batu Biologics Recent Development Table 60. Boehringer Ingelheim Company Information Table 61. Boehringer Ingelheim Business Overview Table 62. Boehringer Ingelheim FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Boehringer Ingelheim FGF-2 Inhibitors Product Portfolio Table 64. Boehringer Ingelheim Recent Development Table 65. Bristol-Myers Squibb Company Company Information Table 66. Bristol-Myers Squibb Company Business Overview Table 67. Bristol-Myers Squibb Company FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Bristol-Myers Squibb Company FGF-2 Inhibitors Product Portfolio Table 69. Bristol-Myers Squibb Company Recent Development Table 70. Celon Pharma Company Information Table 71. Celon Pharma Business Overview Table 72. Celon Pharma FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Celon Pharma FGF-2 Inhibitors Product Portfolio Table 74. Celon Pharma Recent Development Table 75. Debiopharm International Company Information Table 76. Debiopharm International Business Overview Table 77. Debiopharm International FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Debiopharm International FGF-2 Inhibitors Product Portfolio Table 79. Debiopharm International Recent Development Table 80. Eddingpharm Company Information Table 81. Eddingpharm Business Overview Table 82. Eddingpharm FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Eddingpharm FGF-2 Inhibitors Product Portfolio Table 84. Eddingpharm Recent Development Table 85. Eli Lilly and Company Company Information Table 86. Eli Lilly and Company Business Overview Table 87. Eli Lilly and Company FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Eli Lilly and Company FGF-2 Inhibitors Product Portfolio Table 89. Eli Lilly and Company Recent Development Table 90. Hutchison MediPharma Company Information Table 91. Hutchison MediPharma Business Overview Table 92. Hutchison MediPharma FGF-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Hutchison MediPharma FGF-2 Inhibitors Product Portfolio Table 94. Hutchison MediPharma Recent Development Table 95. Principia Biopharma Company Information Table 96. Principia Biopharma Business Overview Table 97. Principia Biopharma FGF-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Principia Biopharma FGF-2 Inhibitors Product Portfolio Table 99. Principia Biopharma Recent Development Table 100. Santa Cruz Biotechnology Company Information Table 101. Santa Cruz Biotechnology Business Overview Table 102. Santa Cruz Biotechnology FGF-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Santa Cruz Biotechnology FGF-2 Inhibitors Product Portfolio Table 104. Santa Cruz Biotechnology Recent Development Table 105. Vichem Chemie Research Company Information Table 106. Vichem Chemie Research Business Overview Table 107. Vichem Chemie Research FGF-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Vichem Chemie Research FGF-2 Inhibitors Product Portfolio Table 109. Vichem Chemie Research Recent Development Table 110. AstraZeneca Company Information Table 111. AstraZeneca Business Overview Table 112. AstraZeneca FGF-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. AstraZeneca FGF-2 Inhibitors Product Portfolio Table 114. AstraZeneca Recent Development Table 115. Amgen Company Information Table 116. Amgen Business Overview Table 117. Amgen FGF-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Amgen FGF-2 Inhibitors Product Portfolio Table 119. Amgen Recent Development Table 120. Novartis Company Information Table 121. Novartis Business Overview Table 122. Novartis FGF-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Novartis FGF-2 Inhibitors Product Portfolio Table 124. Novartis Recent Development Table 125. Eisai Company Information Table 126. Eisai Business Overview Table 127. Eisai FGF-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Eisai FGF-2 Inhibitors Product Portfolio Table 129. Eisai Recent Development Table 130. North America FGF-2 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 131. North America FGF-2 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 132. North America FGF-2 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 133. North America FGF-2 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 134. North America FGF-2 Inhibitors Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. North America FGF-2 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 136. North America FGF-2 Inhibitors Revenue by Country (US$ Million) & (2027-2032) Table 137. Europe FGF-2 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 138. Europe FGF-2 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 139. Europe FGF-2 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 140. Europe FGF-2 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 141. Europe FGF-2 Inhibitors Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. Europe FGF-2 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 143. Europe FGF-2 Inhibitors Revenue by Country (US$ Million) & (2027-2032) Table 144. China FGF-2 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 145. China FGF-2 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 146. China FGF-2 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 147. China FGF-2 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 148. Asia FGF-2 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 149. Asia FGF-2 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 150. Asia FGF-2 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 151. Asia FGF-2 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 152. Asia FGF-2 Inhibitors Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 153. Asia FGF-2 Inhibitors Revenue by Region (US$ Million) & (2021-2026) Table 154. Asia FGF-2 Inhibitors Revenue by Region (US$ Million) & (2027-2032) Table 155. SAMEA FGF-2 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 156. SAMEA FGF-2 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 157. SAMEA FGF-2 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 158. SAMEA FGF-2 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 159. SAMEA FGF-2 Inhibitors Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. SAMEA FGF-2 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 161. SAMEA FGF-2 Inhibitors Revenue by Country (US$ Million) & (2027-2032) Table 162. Research Programs/Design for This Report Table 163. Authors List of This Report Table 164. Secondary Sources Table 165. Primary Sources List of Figures Figure 1. FGF-2 Inhibitors Image Figure 2. Global FGF-2 Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global FGF-2 Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 4. EDP-317 Image Figure 5. Debio-1347 Image Figure 6. CPL-043 Image Figure 7. BAY-1163877 Image Figure 8. AZD-4547 Image Figure 9. ASP-5878 Image Figure 10. Others Image Figure 11. Global FGF-2 Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global FGF-2 Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 13. Clinic Image Figure 14. Hospital Image Figure 15. Others Image Figure 16. Global FGF-2 Inhibitors Market Size (US$ Million) & (2021-2032) Figure 17. Global FGF-2 Inhibitors Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global FGF-2 Inhibitors Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global FGF-2 Inhibitors Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global FGF-2 Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global FGF-2 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global FGF-2 Inhibitors Revenue Market Share by Type (2021-2032) Figure 24. Global FGF-2 Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global FGF-2 Inhibitors Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global FGF-2 Inhibitors Revenue Market Share by Application (2021-2032) Figure 27. North America FGF-2 Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America FGF-2 Inhibitors Revenue Share by Type (2021-2032) Figure 29. North America FGF-2 Inhibitors Revenue Share by Application (2021-2032) Figure 30. North America FGF-2 Inhibitors Revenue Share by Country (2021-2032) Figure 31. United States FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe FGF-2 Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe FGF-2 Inhibitors Revenue Share by Type (2021-2032) Figure 36. Europe FGF-2 Inhibitors Revenue Share by Application (2021-2032) Figure 37. Europe FGF-2 Inhibitors Revenue Share by Country (2021-2032) Figure 38. Germany FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China FGF-2 Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China FGF-2 Inhibitors Revenue Share by Type (2021-2032) Figure 48. China FGF-2 Inhibitors Revenue Share by Application (2021-2032) Figure 49. Asia FGF-2 Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia FGF-2 Inhibitors Revenue Share by Type (2021-2032) Figure 51. Asia FGF-2 Inhibitors Revenue Share by Application (2021-2032) Figure 52. Asia FGF-2 Inhibitors Revenue Share by Region (2021-2032) Figure 53. Japan FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA FGF-2 Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA FGF-2 Inhibitors Revenue Share by Type (2021-2032) Figure 61. SAMEA FGF-2 Inhibitors Revenue Share by Application (2021-2032) Figure 62. SAMEA FGF-2 Inhibitors Revenue Share by Country (2021-2032) Figure 63. Brazil FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt FGF-2 Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • EDP-317
  • Debio-1347
  • CPL-043
  • BAY-1163877
  • AZD-4547
  • ASP-5878
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Advenchen Laboratories
  • ArQule
  • AVEO Pharmaceuticals
  • Batu Biologics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Celon Pharma
  • Debiopharm International
  • Eddingpharm
  • Eli Lilly and Company
  • Hutchison MediPharma
  • Principia Biopharma
  • Santa Cruz Biotechnology
  • Vichem Chemie Research
  • AstraZeneca
  • Amgen
  • Novartis
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 FGF-2 Inhibitors Market by Type
  3. 1.2.1 Global FGF-2 Inhibitors Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 EDP-317
  5. 1.2.3 Debio-1347
  6. 1.2.4 CPL-043
  7. 1.2.5 BAY-1163877
  8. 1.2.6 AZD-4547
  9. 1.2.7 ASP-5878
  10. 1.2.8 Others
  11. 1.3 FGF-2 Inhibitors Market by Application
  12. 1.3.1 Global FGF-2 Inhibitors Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Clinic
  14. 1.3.3 Hospital
  15. 1.3.4 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 FGF-2 Inhibitors Market Dynamics
  1. 2.1 FGF-2 Inhibitors Industry Trends
  2. 2.2 FGF-2 Inhibitors Industry Drivers
  3. 2.3 FGF-2 Inhibitors Industry Opportunities and Challenges
  4. 2.4 FGF-2 Inhibitors Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global FGF-2 Inhibitors Market Perspective (2021-2032)
  2. 3.2 Global FGF-2 Inhibitors Growth Trends by Region
  3. 3.2.1 Global FGF-2 Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global FGF-2 Inhibitors Market Size by Region (2021-2026)
  5. 3.2.3 Global FGF-2 Inhibitors Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global FGF-2 Inhibitors Revenue by Players
  2. 4.1.1 Global FGF-2 Inhibitors Revenue by Players (2021-2026)
  3. 4.1.2 Global FGF-2 Inhibitors Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global FGF-2 Inhibitors Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global FGF-2 Inhibitors Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global FGF-2 Inhibitors Key Players Headquarters & Area Served
  7. 4.4 Global FGF-2 Inhibitors Players, Product Type & Application
  8. 4.5 Global FGF-2 Inhibitors Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global FGF-2 Inhibitors Market CR5 and HHI
  11. 4.6.3 2025 FGF-2 Inhibitors Tier 1, Tier 2, and Tier 3
5 FGF-2 Inhibitors Market Size by Type
  1. 5.1 Global FGF-2 Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global FGF-2 Inhibitors Revenue by Type (2021-2032)
  3. 5.3 Global FGF-2 Inhibitors Revenue Market Share by Type (2021-2032)
6 FGF-2 Inhibitors Market Size by Application
  1. 6.1 Global FGF-2 Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global FGF-2 Inhibitors Revenue by Application (2021-2032)
  3. 6.3 Global FGF-2 Inhibitors Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Advenchen Laboratories
  2. 7.1.1 Advenchen Laboratories Company Information
  3. 7.1.2 Advenchen Laboratories Business Overview
  4. 7.1.3 Advenchen Laboratories FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Advenchen Laboratories FGF-2 Inhibitors Product Portfolio
  6. 7.1.5 Advenchen Laboratories Recent Developments
  7. 7.2 ArQule
  8. 7.2.1 ArQule Company Information
  9. 7.2.2 ArQule Business Overview
  10. 7.2.3 ArQule FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  11. 7.2.4 ArQule FGF-2 Inhibitors Product Portfolio
  12. 7.2.5 ArQule Recent Developments
  13. 7.3 AVEO Pharmaceuticals
  14. 7.3.1 AVEO Pharmaceuticals Company Information
  15. 7.3.2 AVEO Pharmaceuticals Business Overview
  16. 7.3.3 AVEO Pharmaceuticals FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  17. 7.3.4 AVEO Pharmaceuticals FGF-2 Inhibitors Product Portfolio
  18. 7.3.5 AVEO Pharmaceuticals Recent Developments
  19. 7.4 Batu Biologics
  20. 7.4.1 Batu Biologics Company Information
  21. 7.4.2 Batu Biologics Business Overview
  22. 7.4.3 Batu Biologics FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Batu Biologics FGF-2 Inhibitors Product Portfolio
  24. 7.4.5 Batu Biologics Recent Developments
  25. 7.5 Boehringer Ingelheim
  26. 7.5.1 Boehringer Ingelheim Company Information
  27. 7.5.2 Boehringer Ingelheim Business Overview
  28. 7.5.3 Boehringer Ingelheim FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Boehringer Ingelheim FGF-2 Inhibitors Product Portfolio
  30. 7.5.5 Boehringer Ingelheim Recent Developments
  31. 7.6 Bristol-Myers Squibb Company
  32. 7.6.1 Bristol-Myers Squibb Company Company Information
  33. 7.6.2 Bristol-Myers Squibb Company Business Overview
  34. 7.6.3 Bristol-Myers Squibb Company FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bristol-Myers Squibb Company FGF-2 Inhibitors Product Portfolio
  36. 7.6.5 Bristol-Myers Squibb Company Recent Developments
  37. 7.7 Celon Pharma
  38. 7.7.1 Celon Pharma Company Information
  39. 7.7.2 Celon Pharma Business Overview
  40. 7.7.3 Celon Pharma FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Celon Pharma FGF-2 Inhibitors Product Portfolio
  42. 7.7.5 Celon Pharma Recent Developments
  43. 7.8 Debiopharm International
  44. 7.8.1 Debiopharm International Company Information
  45. 7.8.2 Debiopharm International Business Overview
  46. 7.8.3 Debiopharm International FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Debiopharm International FGF-2 Inhibitors Product Portfolio
  48. 7.8.5 Debiopharm International Recent Developments
  49. 7.9 Eddingpharm
  50. 7.9.1 Eddingpharm Company Information
  51. 7.9.2 Eddingpharm Business Overview
  52. 7.9.3 Eddingpharm FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Eddingpharm FGF-2 Inhibitors Product Portfolio
  54. 7.9.5 Eddingpharm Recent Developments
  55. 7.10 Eli Lilly and Company
  56. 7.10.1 Eli Lilly and Company Company Information
  57. 7.10.2 Eli Lilly and Company Business Overview
  58. 7.10.3 Eli Lilly and Company FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Eli Lilly and Company FGF-2 Inhibitors Product Portfolio
  60. 7.10.5 Eli Lilly and Company Recent Developments
  61. 7.11 Hutchison MediPharma
  62. 7.11.1 Hutchison MediPharma Company Information
  63. 7.11.2 Hutchison MediPharma Business Overview
  64. 7.11.3 Hutchison MediPharma FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Hutchison MediPharma FGF-2 Inhibitors Product Portfolio
  66. 7.11.5 Hutchison MediPharma Recent Developments
  67. 7.12 Principia Biopharma
  68. 7.12.1 Principia Biopharma Company Information
  69. 7.12.2 Principia Biopharma Business Overview
  70. 7.12.3 Principia Biopharma FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Principia Biopharma FGF-2 Inhibitors Product Portfolio
  72. 7.12.5 Principia Biopharma Recent Developments
  73. 7.13 Santa Cruz Biotechnology
  74. 7.13.1 Santa Cruz Biotechnology Company Information
  75. 7.13.2 Santa Cruz Biotechnology Business Overview
  76. 7.13.3 Santa Cruz Biotechnology FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Santa Cruz Biotechnology FGF-2 Inhibitors Product Portfolio
  78. 7.13.5 Santa Cruz Biotechnology Recent Developments
  79. 7.14 Vichem Chemie Research
  80. 7.14.1 Vichem Chemie Research Company Information
  81. 7.14.2 Vichem Chemie Research Business Overview
  82. 7.14.3 Vichem Chemie Research FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Vichem Chemie Research FGF-2 Inhibitors Product Portfolio
  84. 7.14.5 Vichem Chemie Research Recent Developments
  85. 7.15 AstraZeneca
  86. 7.15.1 AstraZeneca Company Information
  87. 7.15.2 AstraZeneca Business Overview
  88. 7.15.3 AstraZeneca FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  89. 7.15.4 AstraZeneca FGF-2 Inhibitors Product Portfolio
  90. 7.15.5 AstraZeneca Recent Developments
  91. 7.16 Amgen
  92. 7.16.1 Amgen Company Information
  93. 7.16.2 Amgen Business Overview
  94. 7.16.3 Amgen FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Amgen FGF-2 Inhibitors Product Portfolio
  96. 7.16.5 Amgen Recent Developments
  97. 7.17 Novartis
  98. 7.17.1 Novartis Company Information
  99. 7.17.2 Novartis Business Overview
  100. 7.17.3 Novartis FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Novartis FGF-2 Inhibitors Product Portfolio
  102. 7.17.5 Novartis Recent Developments
  103. 7.18 Eisai
  104. 7.18.1 Eisai Company Information
  105. 7.18.2 Eisai Business Overview
  106. 7.18.3 Eisai FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Eisai FGF-2 Inhibitors Product Portfolio
  108. 7.18.5 Eisai Recent Developments
8 North America
  1. 8.1 North America FGF-2 Inhibitors Revenue (2021-2032)
  2. 8.2 North America FGF-2 Inhibitors Revenue by Type (2021-2032)
  3. 8.2.1 North America FGF-2 Inhibitors Revenue by Type (2021-2026)
  4. 8.2.2 North America FGF-2 Inhibitors Revenue by Type (2027-2032)
  5. 8.3 North America FGF-2 Inhibitors Revenue Share by Type (2021-2032)
  6. 8.4 North America FGF-2 Inhibitors Revenue by Application (2021-2032)
  7. 8.4.1 North America FGF-2 Inhibitors Revenue by Application (2021-2026)
  8. 8.4.2 North America FGF-2 Inhibitors Revenue by Application (2027-2032)
  9. 8.5 North America FGF-2 Inhibitors Revenue Share by Application (2021-2032)
  10. 8.6 North America FGF-2 Inhibitors Revenue by Country
  11. 8.6.1 North America FGF-2 Inhibitors Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America FGF-2 Inhibitors Revenue by Country (2021-2026)
  13. 8.6.3 North America FGF-2 Inhibitors Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe FGF-2 Inhibitors Revenue (2021-2032)
  2. 9.2 Europe FGF-2 Inhibitors Revenue by Type (2021-2032)
  3. 9.2.1 Europe FGF-2 Inhibitors Revenue by Type (2021-2026)
  4. 9.2.2 Europe FGF-2 Inhibitors Revenue by Type (2027-2032)
  5. 9.3 Europe FGF-2 Inhibitors Revenue Share by Type (2021-2032)
  6. 9.4 Europe FGF-2 Inhibitors Revenue by Application (2021-2032)
  7. 9.4.1 Europe FGF-2 Inhibitors Revenue by Application (2021-2026)
  8. 9.4.2 Europe FGF-2 Inhibitors Revenue by Application (2027-2032)
  9. 9.5 Europe FGF-2 Inhibitors Revenue Share by Application (2021-2032)
  10. 9.6 Europe FGF-2 Inhibitors Revenue by Country
  11. 9.6.1 Europe FGF-2 Inhibitors Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe FGF-2 Inhibitors Revenue by Country (2021-2026)
  13. 9.6.3 Europe FGF-2 Inhibitors Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China FGF-2 Inhibitors Revenue (2021-2032)
  2. 10.2 China FGF-2 Inhibitors Revenue by Type (2021-2032)
  3. 10.2.1 China FGF-2 Inhibitors Revenue by Type (2021-2026)
  4. 10.2.2 China FGF-2 Inhibitors Revenue by Type (2027-2032)
  5. 10.3 China FGF-2 Inhibitors Revenue Share by Type (2021-2032)
  6. 10.4 China FGF-2 Inhibitors Revenue by Application (2021-2032)
  7. 10.4.1 China FGF-2 Inhibitors Revenue by Application (2021-2026)
  8. 10.4.2 China FGF-2 Inhibitors Revenue by Application (2027-2032)
  9. 10.5 China FGF-2 Inhibitors Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia FGF-2 Inhibitors Revenue (2021-2032)
  2. 11.2 Asia FGF-2 Inhibitors Revenue by Type (2021-2032)
  3. 11.2.1 Asia FGF-2 Inhibitors Revenue by Type (2021-2026)
  4. 11.2.2 Asia FGF-2 Inhibitors Revenue by Type (2027-2032)
  5. 11.3 Asia FGF-2 Inhibitors Revenue Share by Type (2021-2032)
  6. 11.4 Asia FGF-2 Inhibitors Revenue by Application (2021-2032)
  7. 11.4.1 Asia FGF-2 Inhibitors Revenue by Application (2021-2026)
  8. 11.4.2 Asia FGF-2 Inhibitors Revenue by Application (2027-2032)
  9. 11.5 Asia FGF-2 Inhibitors Revenue Share by Application (2021-2032)
  10. 11.6 Asia FGF-2 Inhibitors Revenue by Country
  11. 11.6.1 Asia FGF-2 Inhibitors Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia FGF-2 Inhibitors Revenue by Country (2021-2026)
  13. 11.6.3 Asia FGF-2 Inhibitors Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA FGF-2 Inhibitors Revenue (2021-2032)
  2. 12.2 SAMEA FGF-2 Inhibitors Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA FGF-2 Inhibitors Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA FGF-2 Inhibitors Revenue by Type (2027-2032)
  5. 12.3 SAMEA FGF-2 Inhibitors Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA FGF-2 Inhibitors Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA FGF-2 Inhibitors Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA FGF-2 Inhibitors Revenue by Application (2027-2032)
  9. 12.5 SAMEA FGF-2 Inhibitors Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA FGF-2 Inhibitors Revenue by Country
  11. 12.6.1 SAMEA FGF-2 Inhibitors Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA FGF-2 Inhibitors Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA FGF-2 Inhibitors Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst